Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
월요일, 8월 31

Summit Therapeutics Inc

SMMTNASDAQ
Trade with Public
Trade with Public
$13.73
-0.60-4.19%
가까이에: Aug 28, 5:00 PM EST
$13.69
-0.0373-0.27%
시간외: Aug 28, 7:45 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Summit Therapeutics Financials

Summit Therapeutics (SMMT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund operations for the next year.
Vandana Singh

PRO
Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) Estimate

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.28) by 32.14 percent. This is a 58.33 percent decrease over losses of $(0.12) per share
Benzinga Newsdesk

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights

Summit Therapeutics Stock Dips After Q1 Financial Report

Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know.
Evette Mitkov

PRO
Summit Therapeutics Q1 Adj. EPS $(0.15) Beats $(0.18) Estimate

Benzinga Newsdesk

Nasdaq 100 Tops Records As Iran Ceasefire Extends, GE Vernova Soars 13%: Stock Market Today

Tech stocks brushed new record highs during midday Wednesday, as a fresh wave of blockbuster corporate earnings propelled mega-cap technology and speculative names higher.
Piero Cingari

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved